This site is intended for healthcare professionals outside the United States

HR+/HER2- BREAST CANCER
Expert-led conference insights from
the 2021 ASCO Annual Meeting

On-demand events.

Panel discussions: HR+/HER2- breast cancer

Please join Prof. Dr. Nadia Harbeck (Germany) and an esteemed panel of experts for 3 webinars where the key data and findings from the HR+/HER2- breast cancer scientific sessions presented at the 2021 ASCO Annual Meeting are discussed.

Program chair.

Professor Nadia Harbeck, MD, PhD

University of Munich, Germany

Professor Nadia Harbeck, MD, PhD, is Head of the Breast Center and is the Chair for Conservative Oncology at the Department of Obstetrics & Gynaecology (OB & GYN), University of Munich (LMU), Germany. She obtained her specialist degree (OB & GYN) at the Technical University of Munich and her medical degree from the University of Munich.

Professor Harbeck is Principal Investigator or steering committee member for numerous breast cancer trials, particularly with novel targeted compounds. Her translational research focuses on prognostic and predictive factors in breast cancer and other solid tumours. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary. Professor Harbeck has authored over 480 papers in peer-reviewed journals (h-index 82) and is Coordinating Editor-in-Chief of Breast Care. She is a panel member of several international breast cancer consensus conferences, such as for advanced breast cancer, breast cancer in young women, and early breast cancer (St Gallen).

In 2020, Professor Harbeck received the 2020 ESMO Lifetime Achievement Award. She has also received numerous other recognitions for her clinical and translational research such as the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award (Emmanuel van der Schueren Lecture), the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest-ranking abstract.

Faculty.

  • Prof. Miguel Martin
  • Prof. Giuseppe Curigliano
  • Prof. Stephen Johnston
  • Dr. Suzette Delaloge
  • Dr. Shani Paluch-Shimon

Miguel Martín, MD, PhD

Hospital General Universitario Gregorio Marañon, Madrid


Professor Miguel Martín is a Medical Oncologist based in Madrid, Spain. Since 1990, Professor Martín has devoted himself to breast cancer research and treatment. He is currently Professor of Medicine at the Complutense University as well as Head of Medical Oncology Service at the Hospital General Universitario Gregorio Marañon, Madrid.

Professor Martín received his medical degree at the University of Valladolid and completed his fellowship and residency at the San Carlos University Hospital, Madrid. He obtained his European Certification in Medical Oncology in London in 1989.

In 1995, Professor Martín created GEICAM (Spanish Group for Breast Cancer Research), a network involving more than 140 Spanish institutions, and has served as Chair of the group since its formation. GEICAM has carried out over 150 clinical, translational and epidemiological studies in the field of breast cancer.

Professor Martín also serves as a member of the Board of Directors and of the Breast Cancer Scientific Steering Committee of TRIO, an international not-for-profit clinical research organization involving 45 different countries. Professor Martín has published over 400 articles in peer-reviewed medical journals. He is a full member of several scientific societies, including ASCO, ESMO, and SEOM. Professor Martín has also previously served as the Spanish ESMO representative, and, in 2017, was awarded the ESMO Award for his contribution to the field of medical oncology.

Giuseppe Curigliano, MD, PhD

University of Milano, Italy

 

Stephen Johnston, MA PhD FRCP

Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London


Stephen Johnston is Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of the Breast Unit at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was appointed Head of Medical Oncology at The Royal Marsden in 2019, having previously been the first director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at The Royal Marsden from 2006–12.

He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and has been Chief Investigator of several phase II/III trials of novel endocrine-based therapeutic approaches in both advanced and early stage disease, including one of the large global adjuvant CDK4/6 inhibitor studies in early breast cancer.

He has published over 260 breast cancer-related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings. He is a member of various scientific committees and international advisory boards, has served as Faculty Member at the American Society for Clinical Oncology, Deputy Editor of the international journal Breast Cancer Research, and is currently Trustee of the UK charity ‘Walk the Walk’.

Suzette Delaloge, MD, MSc

Gustave Roussy, Paris, France


Dr. Delaloge is a medical oncologist and a researcher. She trained in France and Canada. She was Head of the Breast Cancer Department at Gustave Roussy, Paris, France from 2004 until 2021. In 2021, she has been appointed Director of the Cancer Interception Programme at Gustave Roussy.

Dr. Delaloge’s major areas of expertise and development are precision risk-based cancer prevention, real-life data, precision oncology and the organization of care in breast oncology. She has been Chair of the French National Breast Cancer Research Intergroup UCBG until May 2019. She chairs the large H2020 EU-funded MyPeBS project and clinical trial, which aims at demonstrating the value of risk-based breast cancer screening among 85,000 women randomized in five European countries, with the participation of 26 European and American partners.

Dr. Delaloge is an author of more than 275 international, peer-reviewed publications and more than 500 presentations at international conferences (Scopus H-Index: 53). She is a board member of the European Society of Medical Oncology (ESMO) and of the French Society of Breast Care and Breast Pathology, and a member of the American Society of Clinical Oncology (ASCO) and participates in the elaboration of numerous national and international guidelines. She is Breast Cancer Track Chair for the ESMO-Asia conference 2021; prevention track chair for the MAP conference 2021; and will chair the ESMO Breast conference from 2022 to 2024.

Dr. Shani Paluch-Shimon

Hadassah University Hospital, Jerusalem

Dr. Paluch-Shimon is a medical oncologist with a Masters in Epidemiology from the London School of Hygiene & Tropical Medicine. She is director of the Breast Oncology Program at Hadassah University Hospital in Jerusalem, which includes a dedicated service for the care and treatment of young women with breast cancer.  Dr. Paluch-Shimon was the first to establish dedicated services for young women in Israel. Her key areas of clinical interest and research are breast cancer in young women, BRCA-associated breast cancer, triple-negative breast cancer and neo-adjuvant therapies.

She has co-authored over 60 scientific papers and has authored European School of Oncology-ESMO international guidelines on breast cancer in young women, the ESMO clinical practice guidelines on screening and prevention of cancer in individuals with a hereditary breast and ovarian cancer syndrome. She is a member of the ESO-ESMO international consensus panel for the management of advanced breast cancer. Dr. Paluch-Shimon is the subject editor for breast cancer guidelines for the ESMO clinical practice guidelines committee.

Dr. Paluch-Shimon is currently a member of the ESMO Breast Faculty, a core faculty member in the European School of Oncology and co-chair of the European School of Oncology’s Breast Cancer in Young Women Conference. She is a graduate of the Talpiot physician leadership program (Sheba). She was a member of the Israeli Ministry of Health committee evaluating the national breast cancer screening policy and is a member of the Israeli National Cancer Council.

Agenda.

Give us your feedback.

Twitter polls.

Which of the ASCO presentations on HR+/HER2- breast cancer will impact your clinical management the most:

Do you think there is a role for CDK 4/6 inhibitors in early breast cancer?

What are you most excited to hear about within
HR+/HER2- breast cancer (BC)?

Funding.

The content and faculty for this program have been independently developed and/or selected by Springer Healthcare. Novartis Pharmaceutical Corporation provided unconditional funding and as such had no involvement with, or influence on the content and selection of faculty. The content is not intended for use by healthcare professionals in the US. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Opinions expressed do not reflect the views of Springer Healthcare. Springer Healthcare assumes no responsibility for any injury or damage to persons or property arising out of, or related to, any use of the material or to any errors or omissions. Please consult the latest prescribing information from the manufacturer for any products mentioned in this material.